Govt approves Corbevax and Covovax vaccines and anti-viral drug Molnupiravir for restricted use on adults in emergency situations
The Central Drugs Standard Control Organization has given approval to Corbevax vaccine, Covovax vaccine, and anti-viral drug Molnupiravir for restricted use in emergency situations. In a series of tweets, Union Health Minister Mansukh Mandaviya said, Corbevax vaccine is India’s first indigenously developed RBD protein sub-unit vaccine against COVID-19, made by Hyderabad-based firm Biological-E. It is the third vaccine developed in India.
The Nanoparticle Vaccine, Covovax, will be manufactured by Pune-based firm Serum Institute of India.
Mr. Mandaviya said, Molnupiravir will now be manufactured in the country by 13 companies for restricted use under emergency situation for the treatment of adult patients with COVID-19 and who have a high risk of progression of the disease.
He added that Prime Minister Narendra Modi led the battle against COVID-19 from the front and all these approvals will further strengthen the global fight against the pandemic.
In an interaction with All India Radio News, Chairman of India’s COVID-19 Working Group of the National Technical Advisory Group on Immunization Dr. NK Arora said that the approval of these two vaccines and anti-viral drugs is encouraging news for the Covid vaccination campaign.